Rush Oak Park Hospital
Oak Park, Illinois, 60304, United States
NCT Number: NCT01656759
Applying a fibrin spray, after knee device implantation, will help in reducing patient blood loss and decrease the drop in both hemoglobin and hematocrit levels. Also, with decreased blood loss there should be a reduced need for blood transfusions.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 2 / Phase 3
Oak Park, Illinois, 60304, United States
Study Design
Study design and control methods:
This study is designed as a prospective, randomized, double-blinded controlled clinical trial to compare the effect of a fibrin spray applied to the surgical wound as compared to patients not receiving the fibrin spray.
Treatment group:
The subjects will be randomly assigned to the fibrin treatment group or to the control group at the time of the surgery via the opening of a randomly selected sealed envelope. The patient and the independent reviewer will be blinded as to which treatment group the patient is assigned to. This information will be linked to a confidential database for later review by the principal investigator.
Treatment allocation:
All eligible patients (i.e., meeting inclusion criteria and no exclusion criteria) will be treated and observed per the research protocol. All patients will maintain the right to refuse participation and receive a specific treatment of the study if desired.
Trial Population:
The target sample size is 70 patients for both the treatment and control groups (140 total) with each group split evenly between males and females. There will be one actively enrolling surgeon (Dr. Brett Levine). The goal is to enroll a total of 140 subjects experiencing joint pain that warrants a Total knee arthroplasty (TKA). The specific diagnosis for the joint pain will not direct the subjects' assignment or eligibility at the time of surgery. All 140 patients will be enrolled from the office of the primary investigator (Dr. Brett Levine). All indications for TKA will be included unless one of the exclusion criteria is met.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
10cc syringe dose, once at the end of TKA
Other names: Produced by OMRIX Biopharmaceuticals, Ltd.
Time frame: Pre-operative to 1 month
Pre-operative hemoglobin values from routine CBC no earlier than 1 month prior to surgery were compared to post-operative hemoglobin values from routine CBC after surgery.
Time frame: Collected during surgery and in first 2-3 days after surgery
Combination of intraoperative and postoperative blood loss for participants.
Time frame: 3 days
The number of transfusions each patient receives during their postoperative hospitalization.
Time frame: 3 days
Measured as drainage output from postoperative drains during hospitalization.
Rush University Medical Center
Other
Use of a Novel Fibrin Sealant in Total Knee Arthroplasty: A Prospective Randomized Controlled Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01651806
Arthritis, Blood Loss, Surgical
Chicago, Illinois, United States
View Trial DetailsNCT02650856
Arthritis, Hemorrhage
Monterrey, Nuevo León, Mexico
View Trial DetailsNCT01736644
Arthritis, Disability
Epsom, Surrey, United Kingdom
View Trial DetailsNCT01391182
Arthritis, Degenerative Joint Disease
Jacksonville, Florida, United States
View Trial Details